Blog

Obeticholic acid (Ocaliva) has recently been licenced in Canada for the treatment of people with PBC who have not fully responded to, or who are

The American Association for the Study of Liver Diseases published findings that the ASK1 Inhibitor Selonsertib reduced liver fibrosis in stage 2-3 liver fibrosis. In

After waiting 20 years, this month PBC patients have started on their new treatment option, Ocaliva.  For patients who do not respond to ursodeoxycholic acid

Itch is common in people with PBC.  Currently available treatments are not always effective and may have side effects. In PBC, the bile ducts in

CymaBay announced positive interim results from its ongoing low-dose Phase 2 study of seladelpar in patients with primary biliary cholangitis (PBC), a life-threatening and life-limiting

The Canadian PBC Society is excited to share that a new treatment option for PBC is on it’s way, thanks to the recent Canadian approval

 “Liver dialysis” trial begins in the UK/EU with 24 patients at 7 sites – adding 100 EU patients in 2018.The aim is to remove toxins

“Genkyotex Initiates Patient Enrollment into Phase 2 Trial of GKT831 in Primary Biliary Cholangitis” – Read More 

“GENFIT: First Patient enrolled in a Phase 2 Trial recruiting Adults with Primary Biliary Cholangitis (PBC), a Rare Liver Disease ” – Read More